

---

---

**Protein Bound  
3,4-Dihydroxyphenylalanine  
as a Signal for Enhanced  
Antioxidant Defences**

by

Michelle Amy Nelson  
BBiotech(Adv)Hons

A thesis submitted for the degree of  
Doctor of Philosophy  
University of Canberra

March 2008

---

## **Acknowledgements**

A huge thank you to my supervisors Roger, Ruth and Peter, for all your guidance, advice, patience and the occasional push. Your knowledge and expertise has been invaluable and greatly appreciated.

Thank you to my family and friends, for all your support and encouragement over the past four years. I especially want to thank my husband James, for your unending patience, understanding and encouragement to keep going, for your help and advice, and for your unceasing love and support. I am eternally grateful – I couldn't have done it without you.

Thank you also to Jennelle and Suresh for the use of your lab, and to the CCMI and Virus Research groups for your advice and friendship, in particular to Donna for always being there, through the ups and the downs, and for always taking the time to listen to my ideas. Thank you to the rest of the UC Building 3 staff and students for making it a great place to work. In particular, thanks to Claire, Nancy, Ruben, Gillian, Sandy and Maryanne for all your help and encouragement; to Bill and Anne for the use of your plate reader; and to Frank for the use of your spectrophotometer.

Special thanks to Peter Hains and Roger Truscott from the Save Sight Institute, Sydney, for the mass spectrometry analysis. Thank you also to Ken Rodgers and Rachel Dunlop from the Heart Research Institute, Sydney, for your advice early on and for the donation of cells.

This thesis could not have been carried out without the provision of an Australian Postgraduate Award and a grant awarded from the ACT Health and Medical Research Council.

Finally, I would like to thank God for giving me direction, motivation and the strength to persevere.

---

## Table of Contents

Table of Contents.....	i
Index of Figures.....	vi
Index of Tables.....	ix
Publications Arising from this Thesis.....	x
Abbreviations.....	xii
Abstract.....	xiii
<b>1. Literature Review .....</b>	<b>1</b>
1.1. Introduction.....	2
1.2. Oxidative Stress and Damage in Biological Systems.....	2
1.2.1. Stages of Incompletely Controlled Radical Flux.....	3
1.2.2. Protein Oxidation.....	4
1.3. Protein-Bound DOPA.....	7
1.3.1. Generation of PB-DOPA.....	7
1.3.2. Free DOPA.....	8
1.3.3. Relative Potential for Signalling Activity of Free and PB-DOPA.....	9
1.3.4. Physiological Effects of PB-DOPA.....	11
1.3.4.1. Potential Toxic Effects of PB-DOPA.....	12
1.3.4.2. Potential Beneficial Effects of PB-DOPA.....	14
1.3.5. Cell Culture and <i>In Vivo</i> Evidence for the Effects of PB-DOPA.....	14
1.4. Cellular Signalling of Antioxidant Defences.....	20
1.4.1. Antioxidant Defences.....	20
1.4.2. Antioxidant Defences Targeted Specifically Against Protein Oxidation.....	21
1.4.3. Signalling of Antioxidant Defences by Oxidants and Oxidative Products.....	25
1.5. Possible Mechanisms of PB-DOPA Signalling.....	27
1.5.1. PB-DOPA Acting Directly as an Antioxidant.....	27
1.5.2. Involvement of PB-DOPA in Redox Signalling.....	28
1.5.3. Defences Activated Through Protein Regulation or Modification.....	29
1.5.4. Defences Activated Through Regulation of Gene and Protein Expression.....	30
1.5.4.1. Enhancement of Defences Targeted Against Protein Oxidation.....	34
1.5.4.2. Activation of Transcription Factors by PB-DOPA.....	36
1.5.4.3. Activation of the Electrophile Response Element by PB-DOPA.....	39
1.6. Therapeutic Implications.....	43
1.7. Conclusion and Project Objectives.....	44

---

<b>2. General Materials and Methods</b> .....	<b>45</b>
2.1. Materials .....	46
2.2. Cell Culture.....	46
2.2.1. THP-1 Cell Differentiation .....	47
2.2.2. Cell Banking and Thawing .....	47
2.2.3. Trypan Blue Exclusion Assay.....	47
2.2.4. Lactate Dehydrogenase (LDH) Release Assay.....	48
2.3. Protein Analysis .....	49
2.3.1. Micro Bicinchoninic Acid (BCA) <sup>TM</sup> Protein Assay .....	49
2.3.2. Turbidimetric Protein Assay .....	49
2.3.3. One Dimensional Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE).....	49
2.3.4. Protein Detection .....	50
2.3.5. Semi-Dry Protein Transfer.....	51
2.4. Statistical Analysis.....	51
<b>3. Effect of Free and PB-DOPA on Monocyte and Macrophage Cell Viability</b> .....	<b>52</b>
3.1. Introduction.....	53
3.2. Materials and Methods.....	54
3.2.1. Materials .....	54
3.2.2. Cell Culture.....	55
3.2.3. Determination of DOPA Incorporation by Redox-Cycling Staining.....	55
3.2.4. Determination of DOPA Incorporation by Radioactive Tracking.....	56
3.2.5. LDH Assay for the Determination of DOPA Toxicity .....	57
3.2.6. Statistical Analysis.....	57
3.3. Results.....	57
3.3.1. DOPA Incorporation Into THP-1 Cellular Protein .....	57
3.3.2. Effect of Free and PB-DOPA on Cell Viability .....	61
3.4. Discussion.....	65
3.5. Conclusion .....	68
<b>4. Free and PB-DOPA Induce Cellular Protection Against Oxidative Stress</b> .....	<b>69</b>
4.1. Introduction.....	70
4.2. Materials and Methods.....	71
4.2.1. Materials .....	71
4.2.2. Cell Culture.....	71

---

---

4.2.3. AAPH-Induced Oxidative Stress.....	71
4.2.4. Luminol-Enhanced Chemiluminescence for the Detection of AAPH-Derived Radicals.....	72
4.2.5. Statistical Analysis.....	72
4.3. Results.....	73
4.3.1. Combined Cytoprotective Effect of Free and PB-DOPA Under Oxidative Conditions.....	73
4.3.2. Individual Cytoprotective Effect of Free or PB-DOPA Under Oxidative Conditions.....	75
4.3.3. Radical Scavenging Activity of DOPA.....	77
4.3.4. Radical Scavenging Activity of DOPA in More Physiological Conditions.....	79
4.3.5. Anti-Radical Activity of Tyrosine.....	83
4.4. Discussion.....	84
4.5. Conclusion.....	89
<b>5. Free and PB-DOPA Influence the Activity of the Antioxidant Defence System.....</b>	<b>90</b>
5.1. Introduction.....	91
5.2. Materials and Methods.....	92
5.2.1. Materials.....	92
5.2.2. Cell Culture.....	93
5.2.3. Catalase Activity Assay.....	93
5.2.4. Superoxide Dismutase Activity Assay.....	94
5.2.5. NAD(P)H:Quinone Oxidoreductase Activity Assay.....	95
5.2.6. GSH/GSSG Ratio Assay.....	95
5.2.7. Measurement of Cellular Protein Degradation.....	96
5.2.8. Bulk Cellular Chaperone Activity Assay.....	97
5.2.9. Detection of Protein Aggregation.....	98
5.2.10. Statistical Analysis.....	98
5.3. Results.....	98
5.3.1. Effect of Free and PB-DOPA on Enzymatic Antioxidant Activity.....	98
5.3.2. Effect of Free and PB-DOPA on Glutathione Concentration.....	100
5.3.3. Effect of Free and PB-DOPA on Antioxidant Defences Targeted Against Protein Oxidation.....	101
5.4. Discussion.....	105
5.5. Conclusion.....	111

---

---

<b>6. Transcription Factor Activation is Not Induced by Free or PB-DOPA .....</b>	<b>112</b>
6.1. Introduction.....	113
6.2. Materials and Methods.....	114
6.2.1. Materials .....	114
6.2.2. Cell Culture.....	115
6.2.3. Immunofluorescence Staining for the Detection of Transcription Factor Nuclear Translocation .....	115
6.2.4. Nuclear and Cytoplasmic Extraction .....	116
6.2.5. Electromobility Shift Assay.....	116
6.2.6. Statistical Analysis.....	117
6.3. Results.....	118
6.3.1. Transcription Factor Nuclear Translocation .....	118
6.3.2. Transcription Factor DNA Binding Activity.....	126
6.4. Discussion.....	126
6.5. Conclusion .....	129
<b>7. Differential Protein Expression in Response to Free and PB-DOPA .....</b>	<b>130</b>
7.1. Introduction.....	131
7.2. Materials and Methods.....	132
7.2.1. Materials .....	132
7.2.2. Cell Culture.....	133
7.2.3. Separation of Protein by Two-Dimensional Gel Electrophoresis.....	133
7.2.4. PDQuest Analysis of Differential Protein Expression.....	134
7.2.5. Protein Identification Using Matrix Assisted Laser Desorption Ionisation-Time of Flight Peptide Mass Fingerprinting (MALDI-TOF PMF).....	135
7.2.6. Statistical Analysis.....	136
7.3. Results.....	136
7.3.1. Differential Protein Expression in Response to Free and PB-DOPA .....	136
7.3.2. Identification of Differentially Expressed Proteins Induced by Free and PB-DOPA Using MALDI-TOF PMF and MS/MS .....	141
7.3.3. Differential Protein Expression in Response to DOPA Under Conditions that Enhance the Generation of PB-DOPA.....	146
7.3.4. Identification of Differentially Expressed Proteins Induced by an Enhanced Level of PB-DOPA Using MALDI-TOF PMF and MS/MS .....	152
7.4. Discussion.....	156

---

---

7.4.1. Regulation of Protein Expression by Free DOPA and a Low Level of PB-DOPA .....	157
7.4.2. Regulation of Protein Expression by Free DOPA and an Enhanced Generation of PB-DOPA .....	157
7.4.3. Physiological implications of Free and PB-DOPA Induced Regulation of Protein Expression.....	161
7.4.3.1. Enzymatic Antioxidants.....	161
7.4.3.2. Chaperones.....	162
7.4.3.3. Proteins Involved in Cell Cycle Progression .....	163
7.4.3.4. Other Differentially Expressed Proteins .....	165
7.5. Conclusion .....	165
<b>8. General Discussion and Conclusion .....</b>	<b>166</b>
<b>9. References.....</b>	<b>175</b>

---

## Index of Figures

<b>Figure</b>	<b>Title</b>	<b>Page</b>
1.1	Radical-mediated formation of PB-DOPA	5
1.2	PB-DOPA autoxidation	13
1.3	Proposed pathway of PB-DOPA induced activation of AP-1	38
1.4	Proposed pathway of PB-DOPA induced activation of NFκB	40
1.5	Proposed pathway of PB-DOPA induced activation of EpRE	42
3.1	DOPA incorporation into THP-1 cellular protein, detected by redox staining	58
3.2	Incorporation of radiolabelled DOPA into THP-1 cellular protein, with or without the presence of tyrosine	59
3.3	Effect of free and PB-DOPA on monocytic and macrophage-like cell viability	62
3.4	Effect of free DOPA on monocytic and macrophage-like cell viability	63
3.5	Effect of PB-DOPA on monocyte cell viability	64
4.1	Protection against AAPH-induced oxidative stress by a combination of free and PB-DOPA in monocytic and macrophage-like cell lines	74
4.2	Protection against AAPH-induced oxidative stress by free DOPA in THP-1 cells	75
4.3	Protection against AAPH-induced oxidative stress by PB-DOPA in THP-1 cells	77
4.4	Typical light profile obtained from AAPH-radical generation in the presence of free DOPA	78
4.5	Lag phase in radical detection as a result of increasing concentrations of free DOPA	79
4.6	Lag phase in radical detection when reactions are carried out in the presence of 10% (v/v) serum	80
4.7	Lag phase in radical detection as a result of increasing concentrations of free DOPA, carried out in the presence of 10% (v/v) serum	81
4.8	Lag phase in radical detection when reactions are carried out in culture medium containing 10% (v/v) serum at pH 7.4	82
4.9	Typical light profile obtained from hydrogen peroxide-radical generation in the presence of free DOPA	82
4.10	Lag phase in radical detection as a result of increasing concentrations of DOPA and tyrosine	83
4.11	Light profile obtained from AAPH-radical generation in the presence of tyrosine	83
5.1	Catalase activity in response to free and PB-DOPA	99
5.2	Total superoxide dismutase activity in response to free and PB-DOPA	99



---

<b>Figure</b>	<b>Title</b>	<b>Page</b>
5.3	NAD(P)H:quinone oxidoreductase activity in response to free and PB-DOPA	100
5.4	Reduced and oxidised glutathione concentration in response to free and PB-DOPA	101
5.5	Bulk cellular protein degradation in response to free and PB-DOPA	101
5.6	Effect of the level of DOPA-modification on rate of DOPA-modified protein degradation	102
5.7	Inhibition of catalase aggregation by cell lysate	103
5.8	Effect of free and PB-DOPA on bulk chaperone activity	104
5.9	Effect of free and PB-DOPA on AAPH-induced cellular autofluorescence	106
6.1	Effect of free and PB-DOPA on the intensity of transcription factor-specific fluorescence in THP-1 cells	119
6.2	Immunofluorescence microscopy images for Nrf2 analysis	120
6.3	Measurement of Nrf2 nuclear translocation using intensity correlation analysis	121
6.4	Immunofluorescence microscopy images for AP-1 analysis	122
6.5	Measurement of AP-1 nuclear translocation using intensity correlation analysis	123
6.6	Immunofluorescence microscopy images for NFκB analysis	124
6.7	Measurement of NFκB nuclear translocation using intensity correlation analysis	125
6.8	Effect of free and PB-DOPA on the activity and DNA binding capacity of Nrf2, AP-1 and NFκB, detected using EMSA	127
7.1	Two-dimensional gel electrophoresis protein profiles of control and DOPA treated THP-1 cells	137
7.2	Two-dimensional gel electrophoresis protein profiles of control and DOPA treated differentiated THP-1 cells	138
7.3	Cropped THP-1 cellular protein profiles used for PDQuest analysis	139
7.4	Cropped differentiated THP-1 cellular protein profiles used for PDQuest analysis	140
7.5	Differential protein spots identified in control and DOPA treated THP-1 cells	141
7.6	Differential protein spots identified in control and DOPA treated differentiated THP-1 cells	142
7.7	Two-dimensional gel electrophoresis protein profiles of control and DOPA treated THP-1 cells grown under conditions of enhanced PB-DOPA generation	147
7.8	Two-dimensional gel electrophoresis protein profiles of control and DOPA treated differentiated THP-1 cells grown under conditions of enhanced PB-DOPA generation	148

---

---

<b>Figure</b>	<b>Title</b>	<b>Page</b>
7.9	Cropped THP-1 cellular protein profiles, from cultures grown under conditions of enhanced PB-DOPA generation, used for PDQuest analysis	149
7.10	Cropped differentiated THP-1 cellular protein profiles, from cultures grown under conditions of enhanced PB-DOPA generation, used for PDQuest analysis	150
7.11	Differential protein spots identified in control and DOPA treated THP-1 cells grown under conditions of enhanced PB-DOPA generation	151
7.12	Differential protein spots identified in control and DOPA treated differentiated THP-1 cells grown under conditions of enhanced PB-DOPA generation	152
7.13	Effect of tyrosine depletion on vimentin expression	159
7.14	Effect of tyrosine depletion on $\alpha$ -enolase expression	160

---

## Index of Tables

Table	Title	Page
1.1	Selected studies examining the <i>in vitro</i> toxicity of free DOPA	15
1.2	Selected examples of the effects of DOPA administration to a number of <i>in vivo</i> systems	19
1.3	Selected examples of oxidative events that trigger antioxidant defences	25
1.4	DOPA-induced regulation of gene and protein expression involved in antioxidant defences	31
2.1	SDS-PAGE gel preparation	50
3.1	Effect of tyrosine concentration on the incorporation of radiolabelled DOPA into THP-1 cellular proteins	60
3.2	Effect of cycloheximide on the incorporation of radiolabelled DOPA and leucine into THP-1 cellular proteins	60
4.1	Cell viability of monocytic and macrophage-like cell lines following 24 hour exposure to AAPH	73
6.1	Primary and secondary antibodies used for immunofluorescent detection of transcription factor nuclear translocation	115
6.2	Sequences of biotin-end-labelled oligonucleotide probes used in EMSA to investigate transcription factor DNA binding activity	117
7.1	Summary of differentially expressed proteins in THP-1 cells exposed to 100 $\mu$ M DOPA	139
7.2	Summary of differentially expressed proteins in differentiated THP-1 cells exposed to 100 $\mu$ M DOPA	140
7.3	Differentially expressed THP-1 cellular proteins following 24 hour treatment with 100 $\mu$ M DOPA, identified using MALDI-TOF PMF MS	143
7.4	Identification of peptides by MS/MS from proteins differentially expressed in THP-1 cells following exposure to 100 $\mu$ M DOPA	145
7.5	Summary of differentially expressed proteins in THP-1 cells exposed to 100 $\mu$ M DOPA under conditions of enhanced PB-DOPA generation	149
7.6	Summary of differentially expressed proteins in differentiated THP-1 cells exposed to 100 $\mu$ M DOPA under conditions of enhanced PB-DOPA generation	150
7.7	Differentially expressed THP-1 cellular proteins following 24 hour treatment with 100 $\mu$ M DOPA under conditions of enhanced PB-DOPA generation, identified using MALDI-TOF PMF MS	153
7.8	Identification of peptides by MS/MS from proteins differentially expressed in THP-1 cells following exposure to 100 $\mu$ M DOPA under conditions of enhanced PB-DOPA generation	155
7.9	Summary of the differentially expressed proteins induced by PB-DOPA	161

---

## Publications Arising from this Thesis

### Peer Reviewed Journal Articles:

Nelson, M. A., Foxwell, A. R., Tyrer, P. C. and Dean, R. T. (2007) Protein-bound 3,4-dihydroxy-phenylalanine (DOPA), a redox active product of protein oxidation, as a trigger for antioxidant defences. *International Journal of Biochemistry and Cell Biology*, **39**: 879-889

### Conference Presentations and Posters:

Nelson, M. A. (2004) The influence of DOPA on the expression and function of specific lysosomal and proteasomal proteins. Oral presentation, *Divisional Research Institute Corroboree*, University of Canberra, Canberra, Australia

Nelson, M. A., Foxwell, A. R., Tyrer, P. C., Kyd, J. M. and Dean, R. T. (2005) Influences of DOPA on protein degradation and cellular antioxidant defences. Poster presentation, *The Canberra Hospital Annual Research Meeting – Health and Medical Research in the Canberra Region*, The Canberra Hospital, Canberra, Australia

Nelson, M. A. (2005) Physiological functions of DOPA, the good and the bad. Oral presentation, *Divisional Research Institute Corroboree*, University of Canberra, Canberra, Australia

Nelson, M. A., Foxwell, A. R., Tyrer, P. C., Kyd, J. M. and Dean, R. T. (2005) Potential signalling properties of DOPA. Poster presentation, *University of Canberra Showcase*, University of Canberra, Canberra, Australia

Nelson, M. A., Foxwell, A. R., Tyrer, P. C., Kyd, J. M. and Dean, R. T. (2005) Potential signalling properties of PB-DOPA. Poster presentation, *Australian Society for Medical Research, ACT Young Investigators Forum*, Australian National University, Canberra, Australia

Nelson, M. A., Foxwell, A. R., Tyrer, P. C. and Dean, R. T. (2008) Regulation of the cellular antioxidant defence system by protein-bound 3,4-dihydroxyphenylalanine. Oral presentation, *Australian Society for Medical Research, ACT Young Investigators Forum*, The Canberra Hospital, Canberra, Australia

### Journal Articles in Preparation:

Nelson, M. A., Foxwell, A. R., Tyrer, P. C. and Dean, R. T. (2008) Radical sequestration and cellular protection against oxidative stress induced by free and protein-bound 3,4-dihydroxyphenylalanine (DOPA). Based on results presented in chapter 4.

Nelson, M. A., Foxwell, A. R., Tyrer, P. C. and Dean, R. T. (2008) Differential protein expression in response to protein-bound 3,4-dihydroxyphenylalanine (DOPA). Based on results presented in chapter 7.

---

## Abbreviations

AAPH	2,2'-Azobis(amidinopropane) dihydrochloride
AP-1	Activator protein-1
$\alpha$ -syn	$\alpha$ -Synuclein
BAG-1	Bcl-2-associated athanogene
BCA	Bicinchoninic acid
BHT	Butylated hydroxytoluene
BSA	Bovine serum albumin
BSC	Biodegradable counting scintillant
CA-2	Carbonic anhydrase 2
CAP-1	Adenylyl cyclase-associated protein 1
CHIP	Carboxyl terminus of Hsc70-interacting protein
CREB	cAMP response element binding protein
CSF	Cerebrospinal fluid
DAPI	4,6-Diamidino-2-phenylindole
DCPIP	2,6-Dichlorophenolindophenol
DMEM	Dulbecco's Modified Eagles medium
DOPA	3,4-Dihydroxyphenylalanine
DTT	Dithiothreitol
EMSA	Electromobility shift assay
EpRE (ARE)	Electrophile response element (Antioxidant response element)
ERK	Extracellular signal-regulated kinase
FBS	Foetal bovine serum
FCS	Foetal calf serum
GAPDH	Glyceraldehyde-3-phosphate dehydrogenase
GRP78	78 kDa glucose regulated protein
GSH	Reduced glutathione
GSSG	Oxidised glutathione
GTPase Ran	GTP-binding nuclear protein Ran
H <sub>2</sub> O <sub>2</sub>	Hydrogen peroxide
Hsp	Heat shock protein
IEG	Immediate early gene
IPG	Immobilised pH gradient
LDH	Lactate dehydrogenase

---

MALDI-TOF	Matrix assisted laser desorption ionisation-time of flight
MAPK	Mitogen activated protein kinase
MEM	Eagle's minimal essential medium
MS	Mass spectrometry
MS/MS	Tandem mass spectrometry
NADH	Nicotinamide adenine dinucleotide
NBT	Nitroblue tetrazolium
NDK A	Nucleoside diphosphate kinase A
NFκB	Nuclear factor kappa enhanced binding protein
NGF	Nerve growth factor
NQO	NAD(P)H:quinone oxidoreductase
Nrf2	Nuclear factor-erythroid 2 related factor 2
6OHDA	6-Hydroxydopamine
P13K	Phosphatidylinositol-3-kinase
PB-DOPA	Protein-bound 3,4-dihydroxyphenylalanine
PBS	Phosphate buffered saline
PD	Parkinson's disease
PDI	Protein disulfide-isomerase
PMA	Phorbol 12-myristate 13-acetate
PMF	Peptide mass fingerprint
RNS	Reactive nitrogen species
ROS	Reactive oxygen species
SAPK	Stress-activated protein kinase
SDS-PAGE	Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
SOD	Superoxide dismutase
-SOH	Sulphenic acid
TCA	Trichloroacetic acid
TCP	T-complex protein
TEMED	N,N,N',N'-Tetramethylethylenediamine
TRE	12- <i>O</i> -tetradecanoylphorbol 13 acetate (TRA)-response element
WT1	Wilms tumor-1
WTAP	Wilms tumor 1-associating protein

---

## Abstract

Protein-bound 3,4-dihydroxyphenylalanine (PB-DOPA), a long-lived, redox-active product of protein oxidation, is capable of functioning as both a pro- and anti-oxidant. A number of *in vitro* and *in vivo* studies have demonstrated a toxic, non-toxic or even beneficial effect of free DOPA, however little investigation has examined the physiological activity of PB-DOPA. Furthermore, as free DOPA is currently the major treatment available for Parkinson's disease, most studies have focused on the effect of DOPA within neurological cells or tissues, although the presence of PB-DOPA in other locations, for example within atherosclerotic plaques, suggests that broader research is needed to fully understand the physiological effects of both free and PB-DOPA.

The hypothesis presented in this thesis is that under physiological conditions, when little redox active transition metal is available, PB-DOPA can function as a redox signalling molecule, triggering an enhancement of cellular antioxidant defences, with a potentially specific role in the regulation of defences targeted against protein oxidation. Physiological levels of PB-DOPA are very low, however the level on individual proteins can change to a proportionally large degree during oxidative stress, an appropriate property for a signalling molecule. In addition, remarkably elevated levels occur in some pathologies, including atherosclerosis. As an initial and commonly formed product of protein oxidation, PB-DOPA is well placed for a signalling role, promoting a significant up-regulation of antioxidant defences in the early stages of oxidative stress, before extensive damage has occurred. As an initiator of antioxidant defences, PB-DOPA would be potentially useful as a therapeutic for the treatment of diseases involving oxidative stress or the accumulation of oxidative damage.

The main objective of this thesis was, therefore, to examine the effect of PB-DOPA on the cellular antioxidant defence system using monocytic and macrophage-like cells, key cells involved in the formation of atherosclerotic plaques. The incorporation of free DOPA into protein during protein synthesis, a process previously shown to occur both *in vitro* and *in vivo*, was used to generate PB-DOPA. Neither free nor PB-DOPA were found to be toxic to monocytic or macrophage-like cells in culture, but rather were both capable of protecting these cells from oxidative stress. Free DOPA was shown to be capable of directly scavenging radicals, a process that was thought to be in part responsible for the protection induced during oxidative stress. The presence of free and PB-DOPA up-regulated the activity of catalase and

---

NAD(P)H:quinone oxidoreductase, two enzymatic antioxidants, however the activity of superoxide dismutase and the concentration of oxidised and reduced glutathione were not affected. Whilst it was thought that PB-DOPA would have a specific effect on the activity of antioxidant defences targeted against protein oxidation, proteolysis and bulk chaperone activity were not affected by a combination of free and PB-DOPA. Oxidatively-induced protein aggregation, however, was inhibited by the presence of free and PB-DOPA, suggesting that a more specific chaperone regulation may be taking place.

The regulation of gene and protein expression was thought to be one possible mechanism by which PB-DOPA could function as a signalling molecule. To test this hypothesis, the effect of free and PB-DOPA on transcription factor activation and protein expression were investigated. Free and PB-DOPA did not induce the expression or activation of Nrf2, AP-1 or NFκB, three transcription factors thought to be involved in the expressional regulation of genes involved in the antioxidant defence system. However, the expression of a number of proteins, including antioxidants, chaperones and proteins involved in cell cycle progression, were regulated in monocytic and macrophage-like cells following the administration of free DOPA under conditions that resulted in either a high or low level of PB-DOPA generation. The regulated proteins differed between the two conditions, suggesting that the level of PB-DOPA may be a key factor in determining the specific defences targeted.

The results presented in this thesis support the hypothesis that PB-DOPA can function as a signalling molecule, triggering an enhancement of cellular antioxidant defences, with a specific role in the regulation of the chaperone system, a key defence targeted against protein oxidation. This thesis may provide the basis for the potential use of free or PB-DOPA as a therapeutic for diseases known to involve oxidative stress or oxidative damage, however more research will be required to determine if the effects demonstrated in this thesis are also capable of occurring *in vivo*.



# 1. Literature Review

Title page